Medindia

X

ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

Monday, January 4, 2010 Drug News J E 4
Advertisement

Company Contact:

ADVENTRX Pharmaceuticals

Brian Culley, Principal Executive Officer

858-552-0866

Investor Contact:

Lippert/Heilshorn & Associates, Inc.

Don Markley (dmarkley@lhai.com)

310-691-7100

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The Ensign Group Acquires Utah Skilled Nursing Fac...
S
Landmark Consensus Articles Published in Pediatric...